stockrowTwist Bioscience Corporation
TWST Healthcare Biotechnology
Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.
- Revenue
- +23.2%
- EPS
- −264.7%
- Free cash flow
- −7.23%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
Follow TWST
Alert me
Twist Bioscience Corporation (TWST) EPS (diluted)
Twist Bioscience Corporation's EPS (diluted) for fiscal 2025 was −$1.30, compared with −$3.60 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$2.22. Over the past ten years it has ranged from −$25.51 (fiscal 2018) to −$1.30 (fiscal 2025) — the current reading is the highest in ten years. Twist Bioscience Corporation ranks 336th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.30 | — |
| FY2024 | −$3.60 | — |
| FY2023 | −$3.60 | — |
| FY2022 | −$4.04 | — |
| FY2021 | −$3.15 | — |
| FY2020 | −$3.57 | — |
| FY2019 | −$3.92 | — |
| FY2018 | −$25.51 | — |
| FY2017 | −$24.49 | — |
| FY2016 | −$23.58 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.56 | — |
| Mar 2026 | −$0.71 | — |
| Dec 2025 | −$0.50 | — |
| Sep 2025 | −$0.45 | — |
| 31 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $7.37 |
| TGTX TG Therapeutics, Inc. compare | $2.74 |
| PTGX Protagonist Therapeutics, Inc. compare | $1.03 |
| CAI Caris Life Sciences,�Inc. compare | $0.33 |
| IBRX ImmunityBio, Inc. compare | −$0.97 |
| TWST Twist Bioscience Corporation | −$2.22 |
| SYRE Spyre Therapeutics, Inc. compare | −$3.07 |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$5.98 |
| CYTK Cytokinetics, Incorporated compare | −$6.04 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on TWST
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement